Patients with pre-existing vascular risk factor burden such as hypertension and diabetes were likely to be treated with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). The gene discussed is ACE; the disease is diabetes mellitus.